AEON Biopharma, Inc. Announces Pricing of Approximately $20.0 Million Underwritten Public Offering

Core Viewpoint - AEON Biopharma, Inc. has announced a public offering expected to raise approximately $20.0 million to support the development of its botulinum toxin complex, ABP-450, as a biosimilar to BOTOX® for therapeutic uses [1][4]. Offering Details - The offering consists of 40,000,000 Common Units, each including one share of Common Stock or one Pre-Funded Warrant, along with Series A and Series B Registered Common Warrants, both with an exercise price of $0.625 [2]. - The public offering price per Common Unit is set at $0.50, with Pre-Funded Units priced at $0.4999 [2]. - Aegis Capital Corp. has been granted a 45-day option to purchase additional shares and warrants to cover over-allotments, up to 15% of the number of shares and warrants sold in the offering [3]. Use of Proceeds - The capital raised is intended to fund operations through 2025 and facilitate comparative analytical studies required under the 351(k) regulatory pathway [4]. - The net proceeds will be used for general corporate purposes and working capital [4]. Company Background - AEON Biopharma is focused on developing its proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, initially targeting the neurosciences market [8]. - ABP-450 is manufactured in compliance with cGMP and is approved as a biosimilar in Mexico and India, with exclusive development rights in several regions including the U.S. and EU [8].